So far, plenty of beneficial effects of both agents have been investigated separately in diabetic conditions, but the question of whether (and how) PACAP and PARP inhibition could work together against the complex pathomechanisms of hypertension and diabetes in the retina remains unanswered. This evidence concerns the gene PARP1 and diabetes mellitus.